The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Moderna's shares plummeted after cutting its revenue guidance for 2025 due to slow demand for Covid and RSV vaccines.

You’re not imagining it: An unusually large number of Americans are barfing these days. Ninety-one norovirus outbreaks were ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ ... with the continuous lower demand for Covid-19 vaccines. Earlier last year, the vaccine maker announced plans to ...

Today it is driving efforts to create a new generation of therapies known as “cancer vaccines” that aim to ... a drug known as Keytruda (pembrolizumab). Moderna and Merck announced in June ...

In some cases, alternative vaccines may be available, as is the case with the mRNA-based Moderna and Pfizer COVID-19 vaccines, or the RabAvert rabies vaccine cultivated from chicken fibroblasts. Your ...

Vaccines protect babies and children from potentially life-threatening diseases. Widespread childhood vaccination has reduced or eliminated deadly diseases like polio and smallpox. Vaccines currently ...

The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly lower. Moderna (MRNA) was the best-performing stock in the S&P 500 as Barron's called it "too cheap" and named the biotech firm ...